Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tharimmune, Inc. before investing.

In this article, we go over a few key elements for understanding Tharimmune, Inc.’s stock price such as:

• Tharimmune, Inc.’s current stock price and volume
• Why Tharimmune, Inc.’s stock price changed recently
• Upgrades and downgrades for THAR from analysts
• THAR’s stock price momentum as measured by its relative strength

About Tharimmune, Inc. (THAR)

Before we jump into Tharimmune, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary biliary cholangitis. The company also engages in the development of TH023 to treat autoimmune indications; and HS1940, a bispecific biologic against PD-1 and vascular endothelial growth receptor antibody that targets both receptors. It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is based in Red Bank, New Jersey.

Want to learn more about Tharimmune, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tharimmune, Inc..

Tharimmune, Inc.’s Stock Price as of Market Close

As of December 02, 2025, 11:32 AM, CST, Tharimmune, Inc.’s stock price was $2.380.

Tharimmune, Inc. is up 0.85% from its previous closing price of $2.360.

During the last market session, Tharimmune, Inc.’s stock traded between $2.380 and $2.480. Currently, there are approximately 6.24 million shares outstanding for Tharimmune, Inc..

Tharimmune, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tharimmune, Inc. Stock Price History

Tharimmune, Inc.’s (THAR) price is currently down 8.46% so far this month.

During the month of December, Tharimmune, Inc.’s stock price has reached a high of $2.550 and a low of $2.360.

Over the last year, Tharimmune, Inc. has hit prices as high as $9.080 and as low as $0.952. Year to date, Tharimmune, Inc.’s stock is up 17.24%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tharimmune, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there were analysts who downgraded Tharimmune, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Tharimmune, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tharimmune, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tharimmune, Inc. (THAR) by visiting AAII Stock Evaluator.

Relative Price Strength of Tharimmune, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Tharimmune, Inc. has a weighted four-quarter relative price strength of 16.87%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Tharimmune, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tharimmune, Inc. Stock Price: Bottom Line

As of December 2, 2025, Tharimmune, Inc.’s stock price is $2.380, which is up 0.85% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tharimmune, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.